NCT06048653

Brief Summary

Diabetic peripheral neuropathy (DPN) occurs due to long standing hyperglycemia and associated metabolic derangements. Cognitive impairment is a common complication in diabetes mellitus. It is associated with a faster rate of cognitive decline.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Aug 2022

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 2, 2022

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

September 16, 2023

Completed
5 days until next milestone

First Posted

Study publicly available on registry

September 21, 2023

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2024

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2024

Completed
Last Updated

September 21, 2023

Status Verified

September 1, 2023

Enrollment Period

1.4 years

First QC Date

September 16, 2023

Last Update Submit

September 16, 2023

Conditions

Keywords

vagus nerve stimulationcognitive functions

Outcome Measures

Primary Outcomes (6)

  • Attention/ concentration score

    Rehacom will be used to assess score of attention/ concentration domain of cognitive function

    at baseline

  • Attention/ concentration score

    Rehacom will be used to assess score of attention/ concentration domain of cognitive function

    post intervention (after one month)

  • working memory score

    Rehacom will be used to assess score of working memory domain of cognitive function

    at baseline

  • working memory score

    Rehacom will be used to assess score of working memory domain of cognitive function

    post intervention (after one month)

  • Executive function score

    Rehacom will be used to assess score of executive function domain of cognitive function

    at baseline

  • Executive function

    Rehacom will be used to assess score of executive function domain of cognitive function

    post intervention (after one month)

Study Arms (2)

control group

EXPERIMENTAL

The control group (GI) will receive a computer based cognitive rehabilitation program (Rehacom system)

Other: A computer based cognitive rehabilitation program (Rehacom system)

study group

EXPERIMENTAL

The study group (GII) will receive a computer based cognitive rehabilitation program (Rehacom system) in addition to Vagus nerve stimulation.

Other: A computer based cognitive rehabilitation program (Rehacom system)Device: Vagus nerve stimulation

Interventions

Rehacom cognitive rehabilitation software will be used to treat the cognitive dysfunction * Patients will receive training for four weeks, two sessions per week. * Each patient will assume a comfortable sitting position on a chair in front of the screen. * A report will be generated at the end of the session. It will be used for follow up. * Session duration will range from 45 to 60 min. including rest period.

control groupstudy group

stimulation will be applied on cymba conchae of left external ear. A stimulation of frequency of 20 Hz, pulse width of 200 - 300 Ms and intensity of 0.5 mA. The stimulation will be on for 30 s and off for 48 s.The stimulus duration will range from 20 to 40 min.

study group

Eligibility Criteria

Age40 Years - 55 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsDiabetic polyneuropathy female patients
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • patients with diabetic polyneuropathy
  • Female patients.
  • age ranges from 40 to 55 years old.
  • Duration of diabetic illness started since at least three years.
  • Patients with mild to moderate neuropathy according to Toronto clinical neuropathy score
  • Patients with cognitive function ranges from 24 - 15 score according to Mini mental state examination
  • Patients with HbA1c ranges from seven to nine score.
  • Ambulant patients with or without walking aids.
  • Medically and psychologically stable patients without cardiac problems, confirmed by Electro Cardiogram (ECG).
  • able to understand instructions.

You may not qualify if:

  • Type I diabetes mellitus.
  • Severe visual, verbal or acoustic impairments.
  • Sever cognitive dysfunctions or that caused by other cause rather than diabetes mellitus.
  • Polyneuropathy caused by other cause rather than diabetes mellitus.
  • Other neurological problem as stroke.
  • Cardiovascular problems.
  • Metallic implants
  • Illiterate patients.
  • Uncooperative patients.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Faculty of Physical Therapy

Giza, 11432, Egypt

Location

Related Publications (3)

  • Awad N, Gagnon M, Messier C. The relationship between impaired glucose tolerance, type 2 diabetes, and cognitive function. J Clin Exp Neuropsychol. 2004 Nov;26(8):1044-80. doi: 10.1080/13803390490514875.

    PMID: 15590460BACKGROUND
  • Broncel A, Bocian R, Klos-Wojtczak P, Kulbat-Warycha K, Konopacki J. Vagal nerve stimulation as a promising tool in the improvement of cognitive disorders. Brain Res Bull. 2020 Feb;155:37-47. doi: 10.1016/j.brainresbull.2019.11.011. Epub 2019 Nov 29.

    PMID: 31790720BACKGROUND
  • Darwish MH, El-Tamawy MS, Alhirsan SM, El-Anany M, Khalifa HA. Effect of Trans-Auricular Vagal Nerve Stimulation on Cognitive Functions in Diabetic Polyneuropathy Patients. Physiother Res Int. 2025 Apr;30(2):e70063. doi: 10.1002/pri.70063.

MeSH Terms

Interventions

Vagus Nerve Stimulation

Intervention Hierarchy (Ancestors)

Electric Stimulation TherapyTherapeutics

Study Officials

  • Moshera Darwish, Prof. Dr

    Professor of Physical therapy for Neurology

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: The control group (GI) will receive a computer based cognitive rehabilitation program (Rehacom system); and the study group (GII) will receive the same program as (GI) in addition to Vagus nerve stimulation.
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Ass. Prof. Dr of Physical therapy for Neurology

Study Record Dates

First Submitted

September 16, 2023

First Posted

September 21, 2023

Study Start

August 2, 2022

Primary Completion

January 1, 2024

Study Completion

February 1, 2024

Last Updated

September 21, 2023

Record last verified: 2023-09

Data Sharing

IPD Sharing
Will not share

Locations